Is Shopify Stock a Good Buy Now?
eCommerce technology platform Shopify (NASDAQ:SHOP) delivered impressive returns in 2025…
Sell
23
RDY Quote, Financials, Valuation and Earnings
Last price:
$13.41
Seasonality move
:
2.08%
Day range:
$13.38 - $13.52
52-week range:
$12.26 - $16.17
Dividend yield:
0.7%
P/E ratio:
16.41x
P/S ratio:
2.81x
P/B ratio:
2.76x
Volume:
1.3M
Avg. volume:
1.1M
1-year change:
-15.24%
Market cap:
$11.2B
Revenue:
$3.9B
EPS (TTM):
$0.82
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
RDY
Dr. Reddy's Laboratories Ltd.
|
$968.5M | $0.19 | -2.63% | 3.83% | $14.69 |
|
CCM
Concord Medical Services Holdings Ltd.
|
-- | -- | -- | -- | -- |
|
HDB
HDFC Bank Ltd.
|
$5.3B | $0.42 | -62.12% | -3.82% | $43.38 |
|
IBN
ICICI Bank Ltd.
|
$3.4B | $0.40 | -63% | -3.23% | $38.73 |
|
SIFY
Sify Technologies Ltd.
|
$175.7M | -- | 37.72% | -100% | $22.00 |
|
ZLAB
Zai Lab Ltd.
|
$128.1M | -$0.29 | 20.26% | -35.1% | $47.99 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
RDY
Dr. Reddy's Laboratories Ltd.
|
$13.40 | $14.69 | $11.2B | 16.41x | $0.09 | 0.7% | 2.81x |
|
CCM
Concord Medical Services Holdings Ltd.
|
$4.68 | -- | $20.3M | -- | $0.00 | 0% | 0.40x |
|
HDB
HDFC Bank Ltd.
|
$33.10 | $43.38 | $169.4B | 16.47x | $0.38 | 1.14% | 2.26x |
|
IBN
ICICI Bank Ltd.
|
$30.66 | $38.73 | $109.4B | 18.21x | $0.26 | 0.84% | 3.19x |
|
SIFY
Sify Technologies Ltd.
|
$14.99 | $22.00 | $1.1B | 528.82x | $0.00 | 0% | 1.14x |
|
ZLAB
Zai Lab Ltd.
|
$18.55 | $47.99 | $2.1B | -- | $0.00 | 0% | 4.51x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
RDY
Dr. Reddy's Laboratories Ltd.
|
14.04% | -0.123 | 5.65% | 1.12x |
|
CCM
Concord Medical Services Holdings Ltd.
|
273.84% | -1.548 | 77.28% | 0.19x |
|
HDB
HDFC Bank Ltd.
|
52.46% | -0.630 | 38.1% | 4.85x |
|
IBN
ICICI Bank Ltd.
|
39.08% | -1.001 | 22.09% | 2.67x |
|
SIFY
Sify Technologies Ltd.
|
72.21% | 0.764 | 47.71% | 0.58x |
|
ZLAB
Zai Lab Ltd.
|
22.4% | -0.105 | 5.85% | 2.56x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
RDY
Dr. Reddy's Laboratories Ltd.
|
$517.5M | $178.5M | 14.9% | 17.11% | 17.71% | $49.2M |
|
CCM
Concord Medical Services Holdings Ltd.
|
-- | -- | -7.49% | -19.78% | -- | -- |
|
HDB
HDFC Bank Ltd.
|
-- | $3.1B | 6.38% | 14% | 61.91% | -- |
|
IBN
ICICI Bank Ltd.
|
-- | $2.2B | 10.38% | 17.47% | 54.03% | $5.1B |
|
SIFY
Sify Technologies Ltd.
|
$28.6M | $7.2M | -2.56% | -8.9% | 5.96% | -- |
|
ZLAB
Zai Lab Ltd.
|
$69.3M | -$48.9M | -21.74% | -26.7% | -42.05% | -$44.5M |
Dr. Reddy's Laboratories Ltd. vs. Competitors
-
Which has Higher Returns RDY or CCM?
Concord Medical Services Holdings Ltd. has a net margin of 16.2% compared to Dr. Reddy's Laboratories Ltd.'s net margin of --. Dr. Reddy's Laboratories Ltd.'s return on equity of 17.11% beat Concord Medical Services Holdings Ltd.'s return on equity of -19.78%.
Company Gross Margin Earnings Per Share Invested Capital RDYDr. Reddy's Laboratories Ltd.51.32% $0.20 $4.7B CCMConcord Medical Services Holdings Ltd.-- -- $727.8M -
What do Analysts Say About RDY or CCM?
Dr. Reddy's Laboratories Ltd. has a consensus price target of $14.69, signalling upside risk potential of 9.62%. On the other hand Concord Medical Services Holdings Ltd. has an analysts' consensus of -- which suggests that it could grow by 156.41%. Given that Concord Medical Services Holdings Ltd. has higher upside potential than Dr. Reddy's Laboratories Ltd., analysts believe Concord Medical Services Holdings Ltd. is more attractive than Dr. Reddy's Laboratories Ltd..
Company Buy Ratings Hold Ratings Sell Ratings RDYDr. Reddy's Laboratories Ltd.2 2 1 CCMConcord Medical Services Holdings Ltd.0 0 0 -
Is RDY or CCM More Risky?
Dr. Reddy's Laboratories Ltd. has a beta of 0.374, which suggesting that the stock is 62.627% less volatile than S&P 500. In comparison Concord Medical Services Holdings Ltd. has a beta of -1.272, suggesting its less volatile than the S&P 500 by 227.222%.
-
Which is a Better Dividend Stock RDY or CCM?
Dr. Reddy's Laboratories Ltd. has a quarterly dividend of $0.09 per share corresponding to a yield of 0.7%. Concord Medical Services Holdings Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dr. Reddy's Laboratories Ltd. pays 8.91% of its earnings as a dividend. Concord Medical Services Holdings Ltd. pays out -- of its earnings as a dividend. Dr. Reddy's Laboratories Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios RDY or CCM?
Dr. Reddy's Laboratories Ltd. quarterly revenues are $1B, which are larger than Concord Medical Services Holdings Ltd. quarterly revenues of --. Dr. Reddy's Laboratories Ltd.'s net income of $163.4M is higher than Concord Medical Services Holdings Ltd.'s net income of --. Notably, Dr. Reddy's Laboratories Ltd.'s price-to-earnings ratio is 16.41x while Concord Medical Services Holdings Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dr. Reddy's Laboratories Ltd. is 2.81x versus 0.40x for Concord Medical Services Holdings Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RDYDr. Reddy's Laboratories Ltd.2.81x 16.41x $1B $163.4M CCMConcord Medical Services Holdings Ltd.0.40x -- -- --
-
Which has Higher Returns RDY or HDB?
HDFC Bank Ltd. has a net margin of 16.2% compared to Dr. Reddy's Laboratories Ltd.'s net margin of 17.18%. Dr. Reddy's Laboratories Ltd.'s return on equity of 17.11% beat HDFC Bank Ltd.'s return on equity of 14%.
Company Gross Margin Earnings Per Share Invested Capital RDYDr. Reddy's Laboratories Ltd.51.32% $0.20 $4.7B HDBHDFC Bank Ltd.-- $0.44 $131.1B -
What do Analysts Say About RDY or HDB?
Dr. Reddy's Laboratories Ltd. has a consensus price target of $14.69, signalling upside risk potential of 9.62%. On the other hand HDFC Bank Ltd. has an analysts' consensus of $43.38 which suggests that it could grow by 31.04%. Given that HDFC Bank Ltd. has higher upside potential than Dr. Reddy's Laboratories Ltd., analysts believe HDFC Bank Ltd. is more attractive than Dr. Reddy's Laboratories Ltd..
Company Buy Ratings Hold Ratings Sell Ratings RDYDr. Reddy's Laboratories Ltd.2 2 1 HDBHDFC Bank Ltd.3 0 0 -
Is RDY or HDB More Risky?
Dr. Reddy's Laboratories Ltd. has a beta of 0.374, which suggesting that the stock is 62.627% less volatile than S&P 500. In comparison HDFC Bank Ltd. has a beta of 0.570, suggesting its less volatile than the S&P 500 by 42.957%.
-
Which is a Better Dividend Stock RDY or HDB?
Dr. Reddy's Laboratories Ltd. has a quarterly dividend of $0.09 per share corresponding to a yield of 0.7%. HDFC Bank Ltd. offers a yield of 1.14% to investors and pays a quarterly dividend of $0.38 per share. Dr. Reddy's Laboratories Ltd. pays 8.91% of its earnings as a dividend. HDFC Bank Ltd. pays out 19.48% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios RDY or HDB?
Dr. Reddy's Laboratories Ltd. quarterly revenues are $1B, which are smaller than HDFC Bank Ltd. quarterly revenues of $13.6B. Dr. Reddy's Laboratories Ltd.'s net income of $163.4M is lower than HDFC Bank Ltd.'s net income of $2.3B. Notably, Dr. Reddy's Laboratories Ltd.'s price-to-earnings ratio is 16.41x while HDFC Bank Ltd.'s PE ratio is 16.47x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dr. Reddy's Laboratories Ltd. is 2.81x versus 2.26x for HDFC Bank Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RDYDr. Reddy's Laboratories Ltd.2.81x 16.41x $1B $163.4M HDBHDFC Bank Ltd.2.26x 16.47x $13.6B $2.3B
-
Which has Higher Returns RDY or IBN?
ICICI Bank Ltd. has a net margin of 16.2% compared to Dr. Reddy's Laboratories Ltd.'s net margin of 18.8%. Dr. Reddy's Laboratories Ltd.'s return on equity of 17.11% beat ICICI Bank Ltd.'s return on equity of 17.47%.
Company Gross Margin Earnings Per Share Invested Capital RDYDr. Reddy's Laboratories Ltd.51.32% $0.20 $4.7B IBNICICI Bank Ltd.-- $0.42 $63.9B -
What do Analysts Say About RDY or IBN?
Dr. Reddy's Laboratories Ltd. has a consensus price target of $14.69, signalling upside risk potential of 9.62%. On the other hand ICICI Bank Ltd. has an analysts' consensus of $38.73 which suggests that it could grow by 26.31%. Given that ICICI Bank Ltd. has higher upside potential than Dr. Reddy's Laboratories Ltd., analysts believe ICICI Bank Ltd. is more attractive than Dr. Reddy's Laboratories Ltd..
Company Buy Ratings Hold Ratings Sell Ratings RDYDr. Reddy's Laboratories Ltd.2 2 1 IBNICICI Bank Ltd.3 0 0 -
Is RDY or IBN More Risky?
Dr. Reddy's Laboratories Ltd. has a beta of 0.374, which suggesting that the stock is 62.627% less volatile than S&P 500. In comparison ICICI Bank Ltd. has a beta of 0.394, suggesting its less volatile than the S&P 500 by 60.635%.
-
Which is a Better Dividend Stock RDY or IBN?
Dr. Reddy's Laboratories Ltd. has a quarterly dividend of $0.09 per share corresponding to a yield of 0.7%. ICICI Bank Ltd. offers a yield of 0.84% to investors and pays a quarterly dividend of $0.26 per share. Dr. Reddy's Laboratories Ltd. pays 8.91% of its earnings as a dividend. ICICI Bank Ltd. pays out 12.37% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios RDY or IBN?
Dr. Reddy's Laboratories Ltd. quarterly revenues are $1B, which are smaller than ICICI Bank Ltd. quarterly revenues of $8.7B. Dr. Reddy's Laboratories Ltd.'s net income of $163.4M is lower than ICICI Bank Ltd.'s net income of $1.6B. Notably, Dr. Reddy's Laboratories Ltd.'s price-to-earnings ratio is 16.41x while ICICI Bank Ltd.'s PE ratio is 18.21x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dr. Reddy's Laboratories Ltd. is 2.81x versus 3.19x for ICICI Bank Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RDYDr. Reddy's Laboratories Ltd.2.81x 16.41x $1B $163.4M IBNICICI Bank Ltd.3.19x 18.21x $8.7B $1.6B
-
Which has Higher Returns RDY or SIFY?
Sify Technologies Ltd. has a net margin of 16.2% compared to Dr. Reddy's Laboratories Ltd.'s net margin of -2.61%. Dr. Reddy's Laboratories Ltd.'s return on equity of 17.11% beat Sify Technologies Ltd.'s return on equity of -8.9%.
Company Gross Margin Earnings Per Share Invested Capital RDYDr. Reddy's Laboratories Ltd.51.32% $0.20 $4.7B SIFYSify Technologies Ltd.23.73% -$0.04 $653M -
What do Analysts Say About RDY or SIFY?
Dr. Reddy's Laboratories Ltd. has a consensus price target of $14.69, signalling upside risk potential of 9.62%. On the other hand Sify Technologies Ltd. has an analysts' consensus of $22.00 which suggests that it could grow by 46.77%. Given that Sify Technologies Ltd. has higher upside potential than Dr. Reddy's Laboratories Ltd., analysts believe Sify Technologies Ltd. is more attractive than Dr. Reddy's Laboratories Ltd..
Company Buy Ratings Hold Ratings Sell Ratings RDYDr. Reddy's Laboratories Ltd.2 2 1 SIFYSify Technologies Ltd.0 0 0 -
Is RDY or SIFY More Risky?
Dr. Reddy's Laboratories Ltd. has a beta of 0.374, which suggesting that the stock is 62.627% less volatile than S&P 500. In comparison Sify Technologies Ltd. has a beta of 1.032, suggesting its more volatile than the S&P 500 by 3.241%.
-
Which is a Better Dividend Stock RDY or SIFY?
Dr. Reddy's Laboratories Ltd. has a quarterly dividend of $0.09 per share corresponding to a yield of 0.7%. Sify Technologies Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dr. Reddy's Laboratories Ltd. pays 8.91% of its earnings as a dividend. Sify Technologies Ltd. pays out 2.87% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios RDY or SIFY?
Dr. Reddy's Laboratories Ltd. quarterly revenues are $1B, which are larger than Sify Technologies Ltd. quarterly revenues of $120.6M. Dr. Reddy's Laboratories Ltd.'s net income of $163.4M is higher than Sify Technologies Ltd.'s net income of -$3.1M. Notably, Dr. Reddy's Laboratories Ltd.'s price-to-earnings ratio is 16.41x while Sify Technologies Ltd.'s PE ratio is 528.82x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dr. Reddy's Laboratories Ltd. is 2.81x versus 1.14x for Sify Technologies Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RDYDr. Reddy's Laboratories Ltd.2.81x 16.41x $1B $163.4M SIFYSify Technologies Ltd.1.14x 528.82x $120.6M -$3.1M
-
Which has Higher Returns RDY or ZLAB?
Zai Lab Ltd. has a net margin of 16.2% compared to Dr. Reddy's Laboratories Ltd.'s net margin of -30.98%. Dr. Reddy's Laboratories Ltd.'s return on equity of 17.11% beat Zai Lab Ltd.'s return on equity of -26.7%.
Company Gross Margin Earnings Per Share Invested Capital RDYDr. Reddy's Laboratories Ltd.51.32% $0.20 $4.7B ZLABZai Lab Ltd.59.62% -$0.33 $979.3M -
What do Analysts Say About RDY or ZLAB?
Dr. Reddy's Laboratories Ltd. has a consensus price target of $14.69, signalling upside risk potential of 9.62%. On the other hand Zai Lab Ltd. has an analysts' consensus of $47.99 which suggests that it could grow by 158.7%. Given that Zai Lab Ltd. has higher upside potential than Dr. Reddy's Laboratories Ltd., analysts believe Zai Lab Ltd. is more attractive than Dr. Reddy's Laboratories Ltd..
Company Buy Ratings Hold Ratings Sell Ratings RDYDr. Reddy's Laboratories Ltd.2 2 1 ZLABZai Lab Ltd.9 1 0 -
Is RDY or ZLAB More Risky?
Dr. Reddy's Laboratories Ltd. has a beta of 0.374, which suggesting that the stock is 62.627% less volatile than S&P 500. In comparison Zai Lab Ltd. has a beta of 0.835, suggesting its less volatile than the S&P 500 by 16.508%.
-
Which is a Better Dividend Stock RDY or ZLAB?
Dr. Reddy's Laboratories Ltd. has a quarterly dividend of $0.09 per share corresponding to a yield of 0.7%. Zai Lab Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dr. Reddy's Laboratories Ltd. pays 8.91% of its earnings as a dividend. Zai Lab Ltd. pays out -- of its earnings as a dividend. Dr. Reddy's Laboratories Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios RDY or ZLAB?
Dr. Reddy's Laboratories Ltd. quarterly revenues are $1B, which are larger than Zai Lab Ltd. quarterly revenues of $116.2M. Dr. Reddy's Laboratories Ltd.'s net income of $163.4M is higher than Zai Lab Ltd.'s net income of -$36M. Notably, Dr. Reddy's Laboratories Ltd.'s price-to-earnings ratio is 16.41x while Zai Lab Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dr. Reddy's Laboratories Ltd. is 2.81x versus 4.51x for Zai Lab Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RDYDr. Reddy's Laboratories Ltd.2.81x 16.41x $1B $163.4M ZLABZai Lab Ltd.4.51x -- $116.2M -$36M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will The Magnificent 7 Stocks Go Up This Year?
2025 was another banner year for the Magnificent Seven stocks,…
Why Did Planet Labs Stock Rally So Much?
Satellite imaging startup Planet Labs (NYSE:PL), after years of disappointing…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
65
Is GOOG Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Buy
51
Is GOOGL Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Alerts
Buy
100
ATGL alert for Jan 10
Alpha Technology Group Ltd. [ATGL] is up 47.05% over the past day.
Buy
71
NAIL alert for Jan 10
Direxion Daily Homebuilders & Supplies Bull 3X Shs [NAIL] is up 18.52% over the past day.
Buy
54
LGIH alert for Jan 10
LGI Homes, Inc. [LGIH] is up 13.81% over the past day.
